TetraLogic Pharmaceuticals to Present Data From Its SMAC-Mimetic Program at Upcoming AACR Annual Meeting 2014
March 27 2014 - 3:05PM
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today
announced that data from its novel SMAC-Mimetic program will be
presented during presentations at the American Association for
Cancer Research (AACR) Annual Meeting being held April 5-9, 2014 at
the San Diego Convention Center in San Diego, California.
Tetralogic is currently testing its lead SMAC-Mimetic,
birinapant, in Phase 1 and Phase 2 clinical trials for
hematological malignancies and solid tumors. The second
mitochondria-derived activator of caspases (SMAC) exerts its
pro-apoptotic activity by antagonizing multiple members of the
inhibitor of apoptosis (IAP) protein family, which are molecular
targets that have been implicated in various cancers.
Birinapant has been shown to promote apoptosis in cancer cells
through the formation of a caspase-8/RIPK1 complex and induction of
autocrine tumor necrosis factor (TNF). Data presented indicate that
autocrine TNF production induced by birinapant is triggered by the
activation of the caspase-8/RIPK1/p38MAPK axis and may be regulated
by cFLIP isoforms.
Both SMAC-Mimetics (which are bivalent) and monovalent
IAP-inhibitors are being developed for cancer therapy. Owing to the
structural differences between these two classes of therapies, the
biochemical activity of birinapant was compared and contrasted with
several monovalent IAP-inhibitors, and in that comparison,
birinapant showed substantial differences from monovalent
IAP-inhibitors in degrading cIAP1 and cIAP2 associated with TNF
receptor-associated factor 2 (TRAF2).
"These data expand our understanding at the molecular level of
birinapant's unique mechanism of action of establishing apoptosis
in cancer cells," said C. Glenn Begley, Chief Scientific Officer of
TetraLogic. "As the only SMAC-Mimetic in the clinic, birinapant is
a completely novel therapeutic approach to cancer therapy."
The schedule for the TetraLogic oral and poster presentations is
as follows:
- Date & Time: Saturday, April 5, 2014 at
8:15 AM - 8:45 AM Educational Session ED34: From
Chemistry to the Clinic: Pathways for Drug Discovery and
Development, Part 1 – Targeting Protein-Protein Interactions.
Presenter: Stephen M. Condon, TetraLogic
Pharmaceuticals Presentation Title: Discovery and
Clinical Development of a Smac-mimetic (IAP Inhibitor)
Location: Room 29, San Diego Conference
Center
- Session Date and Time: Monday Apr 7, 2014 8:00
AM - 12:00 PM Session ID: Experimental and
Molecular Therapeutics 14 Abstract Number: 1806
Title: Birinapant, a bivalent SMAC-mimetic,
promotes efficient cellular IAP E3 ligase activity and formation of
a pro-apoptotic RIPK1:caspase-8 complex while monovalent IAP
inhibitors are less efficient - implications for therapeutic
utility Authors: Yasuhiro Mitsuuchi, Christopher
A. Benetatos, Thomas Haimowitz, Yijun Deng, Angeline C. Mufalli,
Martin E. Seipel, Jennifer M. Burns, Gurpreet Singh Kapoor, C.
Glenn Begley, and Stephen M. Condon Location: Hall
A-E, Poster Section 33 Poster Board Number:19
- Session Date and Time: Monday Apr 7, 2014 1:00
PM - 5:00 PM Session ID: Molecular and Cellular
Biology 28 Abstract Number: 2278
Title: The SMAC-mimetic birinapant regulates
autocrine TNF production by caspase-8:RIPK1 complex via p38MAPK
pathway Authors: Gurpreet S. Kapoor, Christopher
A. Benetatos, Yasuhiro Mitsuuchi, Eric M. Neiman, Guangyao Yu, Mark
A. McKinlay, John Silke, Stephen M. Condon, and Srinivas K.
Chunduru Location: Hall A-E, Poster Section 17
Poster Board Number:15
- Date & Time: Monday, April 7, 2014, 3:25
PM - 3:45 PM Special Symposium: Data
Reproducibility in Cancer Research: Can You Believe Everything You
Read? Presentation Title: Raising the standards
for biomedical research Presenter: C. Glenn
Begley, TetraLogic Pharmaceuticals Location: Room
8, San Diego Conference Center
About TetraLogic
TetraLogic is a clinical-stage biopharmaceutical company focused
on discovering and developing novel small molecule therapeutics
that mimic the Second Mitochondrial Activator of Caspases, or
SMAC-mimetics, and are designed to cause or enable abnormal cells
that are resistant to the body's immune system to
self-destruct. Birinapant, our clinical-stage product
candidate, is currently being tested in Phase 1 and Phase 2
clinical trials for hematological malignancies and solid
tumors.
CONTACT: Company Contact:
Pete A. Meyers
Chief Financial Officer and Treasurer
TetraLogic Pharmaceuticals Corporation
(610) 889-9900, x103
pete.meyers@tlog.com
Investor Relations Contact:
Ami Bavishi
Burns McClellan, Inc.
(212) 213-0006
abavishi@burnsmc.com
TetraLogic Pharmaceuticals (CE) (USOTC:TLOG)
Historical Stock Chart
From Jun 2024 to Jul 2024
TetraLogic Pharmaceuticals (CE) (USOTC:TLOG)
Historical Stock Chart
From Jul 2023 to Jul 2024